Beacon Financial Group Sells 187 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Beacon Financial Group cut its stake in IQVIA Holdings Inc. (NYSE:IQV) by 4.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,604 shares of the medical research company’s stock after selling 187 shares during the quarter. Beacon Financial Group’s holdings in IQVIA were worth $708,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in IQVIA in the third quarter worth $27,000. Synergy Asset Management LLC bought a new stake in shares of IQVIA during the fourth quarter worth $33,000. Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. lifted its position in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the last quarter. Finally, Concord Wealth Partners bought a new stake in shares of IQVIA during the third quarter worth $57,000. 89.62% of the stock is currently owned by institutional investors.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on IQV shares. Morgan Stanley lifted their target price on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday. Truist Financial reiterated a “buy” rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a research report on Monday. UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. JPMorgan Chase & Co. decreased their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Finally, TD Cowen decreased their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $251.67.

IQVIA Price Performance

IQV opened at $197.64 on Thursday. The business’s 50-day moving average is $200.77 and its two-hundred day moving average is $218.81. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. The firm has a market capitalization of $35.87 billion, a PE ratio of 26.35, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.